Condensed Statements of Operations (USD $)	3 Months Ended		9 Months Ended
	Sep. 30, 2011	Sep. 30, 2010	Sep. 30, 2011	Sep. 30, 2010
Revenue:
Licensing fees	$ 176,922	$ 48,007	$ 513,322	$ 253,525
Peptide and consumer product sales	100,884	45,673	576,165	240,271
Consumer product sales to affiliated company	116,901	0	355,951	0
Total revenue	394,707	93,680	1,445,438	493,796
Cost of revenue:
Cost of peptide and consumer product sales	70,834	29,037	409,829	178,271
Cost of consumer product sales to affiliated company	56,961	0	191,486	0
Total cost of revenue	127,795	29,037	601,315	178,271
Gross profit	266,912	64,643	844,123	315,525
Operating expenses:
Research and development	109,221	196,752	425,131	572,617
Marketing and business development	225,732	193,027	674,187	480,016
General and administrative	327,162	431,202	1,043,843	1,138,062
Accounting, legal and professional fees	168,043	107,263	477,676	414,038
Depreciation and amortization	27,845	28,430	82,609	86,803
Total operating expenses	858,003	956,674	2,703,446	2,691,536
Loss from operations	(591,091)	(892,031)	(1,859,323)	(2,376,011)
Other income (expense):
Interest income	704	1,027	2,836	2,386
Interest expense on convertible notes payable	0	(38,796)	0	(103,069)
Interest expense on convertible notes payable, related party	0	(156,274)	0	(426,553)
Accretion of discount on convertible notes payable	0	(10,675)	0	(29,861)
Accretion of discount on convertible notes payable, related party	0	(18,427)	0	(51,604)
Equity in loss of affiliated company	(23,373)	(4,013)	(74,446)	(4,013)
Change in fair value of option to purchase interest in affiliated company	8,143	0	(9,293)	0
Other income (expense), net	(14,526)	(227,158)	(80,903)	(612,714)
Net loss and comprehensive loss	$ (605,617)	$ (1,119,189)	$ (1,940,226)	$ (2,988,725)
Basic and diluted net loss per share (in Dollars per share)	$ (0.01)	$ (0.04)	$ (0.04)	$ (0.12)
Weighted average shares outstanding (in Shares)	49,720,255	25,653,512	49,720,255	25,653,512